Funding News

A €115 Million Deal Just Expanded Access to the World's Only Approved Desensitization Therapy for Kidney Transplant Patients — Imlifidase Is Coming to MENA

By Mustafa Shariff, Editor in Chief · June 08,2026 · 2 min read

Mustafa Shariff, Editor in Chief — A €115 Million Deal Just Expanded Access to the World's Only Approved Desensitization Therapy for Kidney Transplant Patients — Imlifidase Is Coming to MENA

Summary

Hansa Biopharma + SERB IDEFIRIX €115 Million Deal: What Imlifidase Means for Kidney Transplant Access
Hansa Biopharma has licensed IDEFIRIX to SERB Pharmaceuticals for EU and MENA. Here is the full story of this first-in-class therapy and its significance for transplant medicine.

"SERB is committed to expanding access to transplantation for highly sensitized patients who currently have very limited alternatives. We will leverage our deep expertise and established platform across Europe and MENA to expand the clinical impact of IDEFIRIX."

Sweden-based Hansa Biopharma AB and SERB Pharmaceuticals SA have entered into an exclusive licensing agreement for the development and commercialisation of IDEFIRIX (imlifidase) across the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland, and the MENA region. The transaction value is €115 million — comprising €110 million upfront and an additional €5 million contingent on the European Medicines Agency accepting the full approval filing for IDEFIRIX.

The deal gives Hansa Biopharma the financial foundation — in Renée Aguiar-Lucander's words — to assure an optimised US launch and a pathway to profitability, subject to anticipated US FDA regulatory approval by December 19, 2026. For SERB, a privately owned global specialty pharmaceutical company with 25 or more years of experience in rare diseases and rare medical emergencies, the agreement leverages an established commercial platform across Europe and MENA to expand access to a therapy that addresses a specific, profound clinical unmet need.

What IDEFIRIX Does and Why It Is Unique

Kidney transplantation is the gold standard treatment for end-stage renal disease — superior in both outcomes and quality of life to dialysis for most patients. The challenge is immunological compatibility: the recipient's immune system may carry antibodies against the donor's human leukocyte antigens. When these donor-specific antibodies are present and a crossmatch test between recipient blood and donor cells is positive, transplantation carries very high risk of hyperacute rejection — immediate destruction of the transplanted kidney by the recipient's immune system.

For highly sensitised patients — those who have developed broad antibody responses from prior transplants, multiple blood transfusions, or pregnancies — finding a compatible donor through the standard system of waiting for a negative crossmatch can take decades. Some highly sensitised patients wait their entire lives on dialysis without receiving a compatible organ. This is the clinical problem IDEFIRIX addresses.

Imlifidase is an enzyme derived from Streptococcus pyogenes that specifically cleaves immunoglobulin G antibodies at the hinge region, inactivating all classes of IgG antibodies within two to six hours. When administered to a highly sensitised kidney transplant candidate before a planned transplant, imlifidase rapidly eliminates the donor-specific antibodies that were causing the positive crossmatch — converting an incompatible crossmatch to a negative one and allowing transplantation to proceed. The European Commission granted conditional approval to IDEFIRIX for exactly this indication: desensitisation of highly sensitised adult kidney transplant candidates with a positive crossmatch against an available deceased donor.

The India Transplant Medicine Connection

India performs approximately 3,500-4,000 kidney transplants annually — a number that is growing rapidly but remains far below the clinical need. The country's kidney failure burden, driven by high rates of diabetes, hypertension, and IgA nephropathy, creates a large waiting pool of patients who need transplantation. A proportion of these are highly sensitised, having received prior transplants, multiple blood transfusions, or having undergone pregnancies — and for them, the immunological barriers to finding a compatible donor are severe.

IDEFIRIX is not yet approved in India, and its path to Indian regulatory approval will require a separate CDSCO review process. But the SERB deal's coverage of MENA — which includes Indian Ocean region markets — places the drug in a geography adjacent to India and creates a commercial precedent for pricing and access models that will inform any eventual Indian market entry. More immediately, the Hansa-SERB deal is a story about transplant medicine innovation reaching the MENA patient populations that BHC Media's audience operates within and adjacent to.

BHC Perspective

At Bengaluru Health Community, the Hansa-SERB IDEFIRIX deal is a window into the rare disease and transplant medicine space that is directly relevant to India's growing transplant infrastructure. Apollo, Manipal, Narayana, and Aster have all been growing their organ transplant programmes. The clinical problem that IDEFIRIX addresses — highly sensitised patients who cannot find compatible donors — exists in India at significant scale. Understanding global pipelines for rare disease and transplant medicine is essential context for BHC's clinical and pharmaceutical founders working in these specialties.

Frequently Asked Questions

Q: What is IDEFIRIX (imlifidase)?
A: A first-in-class enzyme therapy from Streptococcus pyogenes that cleaves all classes of IgG antibodies within 2-6 hours. Conditionally approved by the European Commission for desensitisation of highly sensitised adult kidney transplant candidates with positive crossmatch against an available deceased donor — allowing transplantation in patients who would otherwise be rejected.

Q: What is the Hansa-SERB deal?
A: An exclusive licensing agreement valued at €115 million (€110M upfront + €5M on EMA filing acceptance) for SERB to develop and commercialise IDEFIRIX across EU, UK, Switzerland, Norway, Iceland, Liechtenstein, and MENA.

Q: Why is this relevant for India?
A: India performs 3,500-4,000 kidney transplants annually with a large unmet need from highly sensitised patients who cannot find compatible donors. IDEFIRIX addresses this specific clinical gap. While not yet approved in India, the drug's MENA coverage places it in the adjacent region and creates precedents for future Indian access.